Combination of chemotherapy with docetaxel / cisplatin / fluorouracil (DCF) and autologous gamma/delta T cell transfer therapy for esophageal cancer.

Combination of chemotherapy with docetaxel / cisplatin / fluorouracil (DCF) and autologous gamma/delta T cell transfer therapy for esophageal cancer. - DCF and gamma/delta T cell therapy for esophageal cancer.

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008097

Enrollment

Registered

2012-06-04

Start date

2012-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal cancer

Interventions

-Docetaxel 60mg/m2 on day1 of each cycle -Cisplatin 60mg/m2 on day1 of each cycle -Fluorouracil 600mg/m2/day continuous infusion on days 1 through 5 each cycle -Autologous gamma/delta T cells on d

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Recurrent or unresectable advanced esophageal cancer patients who are eligible for DCF chemotherapy and meet the following: - Pathological Diagnosed of esophageal cancer; - Diagnosis of recurrent esophageal cancer by imaging; - Life-expectancy is more than 3 months; - Performance status is 0-1; - No serious abnormality in heart, lung, bone marrow, liver, and renal functions.

Exclusion criteria

Exclusion criteria: Patients who have: - Pulmonary fibrosis or interstitial pneumonia, including their history or predisposition; - Treated with chemoradiotherapy; - Active enteritis; - Active autoimmune diseases, - Active infections; - Other cancers; - Other serious complications; - Continuous systemic administration of steroids.

Design outcomes

Primary

Measure	Time frame
Safety	—

Secondary

Measure	Time frame
Efficacy - Progression-free survival - Overall survival - Response rate - Survival rate (1 and 2 years) - Response of tumor-related markers - Immunological responses	—

Countries

Japan

Contacts

Public ContactKazuhiro Kakimi

The University of Tokyo Hospital Department of Immunotherapeutics

immunotherapy-admin@umin.ac.jp03-5805-3161

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026